Corteva (NYSE:CTVA) Price Target Raised to $95.00

Corteva (NYSE:CTVA) had its target price hoisted by Oppenheimer from $89.00 to $95.00 in a research report report published on Thursday morning,Benzinga reports. They currently have an outperform rating on the stock.

Several other research analysts have also recently issued reports on the stock. CICC Research raised their target price on shares of Corteva from $80.00 to $93.00 and gave the stock an “outperform” rating in a report on Wednesday, May 13th. UBS Group lowered their price target on shares of Corteva from $90.00 to $86.00 and set a “neutral” rating on the stock in a report on Tuesday, June 9th. Deutsche Bank Aktiengesellschaft increased their price target on Corteva from $90.00 to $100.00 in a research report on Monday, May 11th. Wells Fargo & Company lifted their price objective on Corteva from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Tuesday, April 21st. Finally, Berenberg Bank boosted their price objective on Corteva from $68.00 to $78.00 and gave the company a “hold” rating in a report on Thursday, March 26th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat, Corteva has an average rating of “Moderate Buy” and a consensus price target of $90.19.

Corteva Price Performance

Shares of NYSE CTVA opened at $89.23 on Thursday. Corteva has a 52 week low of $60.53 and a 52 week high of $89.39. The business’s 50 day moving average price is $81.39 and its 200 day moving average price is $78.91. The company has a quick ratio of 1.03, a current ratio of 1.47 and a debt-to-equity ratio of 0.07. The firm has a market cap of $59.68 billion, a P/E ratio of 52.49, a P/E/G ratio of 2.70 and a beta of 0.56.

Corteva (NYSE:CTVA) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $1.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.18 by $0.32. Corteva had a net margin of 6.50% and a return on equity of 9.95%. The company had revenue of $4.91 billion during the quarter, compared to analyst estimates of $4.64 billion. During the same period last year, the firm posted $1.13 EPS. Corteva’s revenue for the quarter was up 11.0% compared to the same quarter last year. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. On average, sell-side analysts expect that Corteva will post 3.76 earnings per share for the current year.

Corteva Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Tuesday, September 1st will be issued a dividend of $0.18 per share. The ex-dividend date of this dividend is Tuesday, September 1st. This represents a $0.72 dividend on an annualized basis and a yield of 0.8%. Corteva’s dividend payout ratio is 42.35%.

Institutional Trading of Corteva

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CTVA. Vanguard Group Inc. boosted its stake in shares of Corteva by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 80,536,951 shares of the company’s stock worth $5,398,392,000 after acquiring an additional 317,538 shares in the last quarter. State Street Corp increased its stake in shares of Corteva by 3.7% in the 4th quarter. State Street Corp now owns 36,570,876 shares of the company’s stock valued at $2,451,346,000 after purchasing an additional 1,290,071 shares in the last quarter. Franklin Resources Inc. raised its holdings in Corteva by 4.3% in the 4th quarter. Franklin Resources Inc. now owns 19,537,500 shares of the company’s stock worth $1,309,599,000 after purchasing an additional 805,873 shares during the period. Harris Associates L P raised its holdings in Corteva by 168.1% in the 4th quarter. Harris Associates L P now owns 17,026,221 shares of the company’s stock worth $1,141,268,000 after purchasing an additional 10,675,052 shares during the period. Finally, Northern Trust Corp boosted its position in Corteva by 5.0% during the fourth quarter. Northern Trust Corp now owns 11,731,834 shares of the company’s stock worth $786,385,000 after purchasing an additional 562,550 shares in the last quarter. Institutional investors and hedge funds own 81.54% of the company’s stock.

Trending Headlines about Corteva

Here are the key news stories impacting Corteva this week:

• Positive Sentiment: Oppenheimer raised its price target on Corteva to $95 from $89 and kept an “outperform” rating, signaling confidence in further upside for the stock.
• Positive Sentiment: Zacks upgraded Corteva to Rank #2 (Buy), citing improving earnings prospects ahead of the company’s upcoming results.
• Positive Sentiment: Analysts expect Q2 earnings growth as premium seed demand, new products, and productivity gains help offset pricing and inflation pressure. Corteva Set to Report Q2 Earnings: What Investors Should Expect
• Neutral Sentiment: Corteva declared a quarterly dividend of $0.18 per share, payable September 15 to shareholders of record on September 1, which supports the stock’s income profile but is not a major growth catalyst. Corteva Declares Quarterly Dividend
• Neutral Sentiment: The company is set to report Q2 earnings soon, and investors are awaiting confirmation that demand and operating efficiency trends are holding up. Corteva (CTVA) Projected to Release Quarterly Earnings on Thursday

About Corteva

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.